Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy

Diabetic Medicine

Volumn 21, Issue 12, 2004, Pages 1292-1297

  Tashimo, A ^a   Mitamura, Yoshinori ^a   Nagai, S ^a   Nakamura, Y ^b   Ohtsuka, K ^a   Mizue, Y ^c   Nishihira, J ^c  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Obihiro Kousei Hospital   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aqueous humour; Diabetic retinopathy; Macrophage migration inhibitory factor; Monocyte chemotactic protein 1

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOGENESIS;

ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; RETINAL DISEASES; STATISTICS, NONPARAMETRIC; VITREORETINOPATHY, PROLIFERATIVE;

EID: 10244241784     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01334.x     Document Type: Article

References (22)

1. Schröder S, Palinski W, Schmid-Schöbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
2. Knott RM, Robertson M, Muckersie E, Folefac VA, Fairhurst FE, Wileman SM et al. A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia 1999; 42: 870-877.
3. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Stricter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995; 14: 1045-1053.
4. Abu El-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997; 123: 599-606.
5. Capeans C, de Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998; 18: 546-550.
6. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001; 215: 415-418.
7. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed type hypersensitivity. Science 1966; 153: 80-82.
8. Matsushima K, Larsen CG, Dubois GC, Oppenheim JJ. Purification and characterization of novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-1490.
9. Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991; 78: 1112-1116.
10. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2000; 84: 636-639.
11. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology 1991; 98: 823-833.
12. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
13. Burgos R, Mateo C, Cantón A, Hernández C, Mesa J, Simó R. Vitreous levels of IGF-1, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy. Diabetes Care 2000; 23: 80-83.
14. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Differentiation of subpopulations. Br J Ophthalmol 1993; 77: 731-733.
15. Yoshimoto T, Nishihira J, Tada M, Houkin K, Abe H. Induction of macrophage migration inhibitory factor messenger ribonucleic acid in rat forebrain by reperfusion. Neurosurgery 1997; 41: 648-653.
16. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 2003; 308: 474-479.
17. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966; 56: 72-77.
18. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181-191.
19. Pan JH, Lindholt JS, Sukhova GK, Baugh JA, Henneberg EW, Bucala R et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg 2003; 37: 628-635.
20. Matsuda A, Tagawa Y, Yoshida K, Matsuda H, Nishihira J. Expression of macrophage migration inhibitory factor in rat retina and its immunohistochemical localization. J Neuroimmunol 1997; 77: 85-90.
21. Yabunaka N, Nishihira J, Mizue Y, Tsuji M, Kumagai M, Ohtsuka Y et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000; 23: 256-258.
22. Elner SG, Strieter RM, Elner VM, Rollins BJ, Del Monte MA, Kunkel SL. Monocyte chemotactic protein gene expression by cytokine treated human retinal epithelial cells. Lab Invest 1991; 64: 819-825.